Akihiro Ohba: Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer

Akihiro Ohba, Medical Oncologist at Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, posted on X about recent paper by him as first author, titled “Trastuzumab Deruxtecan in HER2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial” published on Journal of Clinical Oncology.

Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Takuji Okusaka.

“Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial | Journal of Clinical Oncology.”

Source: Akihiro Ohba/X